Aadi Bioscience reports Q3 2023 results; no financial details in filing

Whitehawk Therapeutics, Inc.

2023-Q3 EPS reported -$1.84 revenue$18,028,000

Press release for Q3 2023 results issued on November 8, 2023.
No revenue, EPS, or other specific figures are included in this filing text.
Investors need to review the full press release for complete financial data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Aadi Bioscience, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.